The clear path to small molecule visualization & quantification

About Immusmol

About Immusmol

Immusmol was initially founded in 2012 in Bordeaux by immunologist Dr. Alban Bessède, to develop anti-hapten antibodies targeting kynurenines for diagnostic and therapeutic applications. 

Over the past decade, Immusmol speciliazed in the development of antibodies against low molecular weight compounds (<900 Daltons), eventually building a portfolio of unique primary antibodies and ELISA kits for research use.

small-molecule-antibody

Immusmol at a glance

Unique primary antibodies
0 +

We develop monoclonal & polyclonal antibodies and staining procedures for the visualization of small molecules in cells & tissues.

ELISAs cross-validated by LC-MS
0 +

Our team develops highly sensitive ELISA kits to measure amino acids and their metabolites in biological samples.

Clients served worldwide
0 +

We deliver our products worldwide through Fedex and developed a network of trusted distributors in America, Europe, Africa, Asia, and Oceania.

What we stand for

Validated products

Our products are systematically validated before we start their distribution.

Scientific support

Our team supports clients effectively to ensure they get results.

In-house R&D

We keep developing new products for the analysis of metabolic pathways.

200+ citations in the literature

They published with our products:

Our team

Founder & CEO
Trained in immunology, Alban has a strong interest in tryptophan metabolism in cancer, and co-authored over 30 papers in immuno-oncology.
Chief Operating Officer
Holding a 20-year experience in the biotech industry, Loïc is in charge of distributor interactions, finance, and overall management.

Dominique Bodet, PhD

R&D Director
Trained in biochemistry, Dominique has been developing anti–hapten antibodies and immunoassays for the past 25 years. He is the main contact for customer support.
Marketing Director
Pierre has a 15-year experience in scientific communication & marketing. Back in 2014, he launched the first e-commerce website of Immusmol.

In 2015, Immusmol launched Explicyte, a CRO dedicated to precision oncology, offering preclinical and translational services to the industry

Our partners & supports

Founded in 2012 by Alban Bessede, PhD in Immunology, with the support of Schiever retail group, Immusmol specializes in developing antibodies directed against small molecules. Supported by public institutions such as Bpifrance and the Regional Council of Nouvelle-Aquitaine, Immusmol is established in Bordeaux, France. The Immusmol team is made up of around twenty talents with different backgrounds and application fields, bringing their expertise and experience to the company. We aim to become a natural choice for small molecule antibody development, hence working with distributors from all over the globe and collaborating with a worldwide network of scientists. Immusmol stands for antibodies against small molecules. While traditional antibodies only recognize large molecules such as proteins, Immusmol designs and develops antibodies capable of targeting low molecular weight entities, below 900 Daltons, that can be used for conventional staining applications as well as in the scope of novel immunoassays development. Fully compatible with existing antibody-based technologies, small molecule antibodies are opening new possibilities in research diagnostic and therapeutic applications.
Search
×
3
    3
    Your Cart